Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effect of Tesaglitazar 1 mg once daily on the Pharmacokinetics of Metformin Following Addition of Tesaglitazar to Metformin Treatment twice daily in Patients with Type 2 Diabetes.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 May 2011
Price :
$35
*
At a glance
- Drugs Tesaglitazar (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors AstraZeneca AB
- 17 May 2011 New trial record